论文部分内容阅读
目的 探讨恶性血液病患者血小板输注无效与淋巴细胞毒试验 (LCT)同种免疫的关系。方法 对1997- 12～ 2 0 0 2 - 12广东省人民医院 5 9例恶性血液病患者经多次血小板输注后进行淋巴细胞毒试验 ,进行血小板校正增加值测定 (CCI) ,探讨LCT与血小板输注无效之间的关系。结果 患者中 ,LCT阳性率 38 6 % ;其中 ,急性淋巴细胞白血病 (ALL)LCT阳性率 4 6 1% ;急性非淋巴细胞白血病 (AML)LCT阳性率 34 8% ;ALL与AML之间LCT阳性率差异无显著性意义 (χ2 =0 4 5 2 ,P >0 0 5 )。CCI无效组 32 2 % ,其中LCT阳性者 5 7 9% ;CCI有效组 6 7 8% ,其中LCT阳性者 12 5 %。CCI无效组与CCI有效组LCT阳性率差异有显著性 (χ2 =13 4 3,P <0 0 1)。结论 发现大多数患者LCT滴度越高 ,发生血小板输注无效的可能性就越大。
Objective To investigate the relationship between platelet transfusion failure and lymphocyte cytotoxicity (LCT) alloimmunity in patients with hematologic malignancies. Methods Fifty-nine patients with hematologic malignancies from Guangdong Provincial People’s Hospital between 1997- 12 and 2000-12 were subjected to multiple platelet transfusions and then to lymphocytotoxicity test. The value of platelet correction (CCI) was measured to investigate the relationship between LCT and platelet The relationship between invalid infusion. Results The positive rate of LCT was 38 6% in patients. The positive rate of LCT in acute lymphoblastic leukemia (ALL) was 46.1%. The positive rate of LCT in acute non-lymphocytic leukemia (AML) was 34.8%. LCT positive between ALL and AML Rate difference was not significant (χ2 = 0 4 5 2, P> 0 0 5). CCI invalid group 32 2%, of which LCT positive 57.9%; CCI effective group 67.8%, LCT positive 125%. The difference of LCT positive rate between CCI invalid group and CCI effective group was significant (χ2 = 1343, P <0.01). Conclusions Most LCT titers were found to be more likely to be ineffective for platelet transfusion.